Www.pbm.va.gov

VHA PBM Intranet site. EXECUTIVE SUMMARY . Dexlansoprazole, the R-enantiomer of lansoprazole, is the sixth proton pump inhibitor (PPI) marketed in the U.S. for the healing and maintenance of erosive esophagitis and the fifth PPI to be approved by the Food and Drug Administration (FDA) for symptomatic treatment of nonerosive gastroesophageal reflux disease (GERD). Dexlansoprazole is formulated ... ................
................